RU2019124982A - Природные клетки-киллеры и их применение - Google Patents
Природные клетки-киллеры и их применение Download PDFInfo
- Publication number
- RU2019124982A RU2019124982A RU2019124982A RU2019124982A RU2019124982A RU 2019124982 A RU2019124982 A RU 2019124982A RU 2019124982 A RU2019124982 A RU 2019124982A RU 2019124982 A RU2019124982 A RU 2019124982A RU 2019124982 A RU2019124982 A RU 2019124982A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- population
- cell precursors
- csf
- duration
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims 13
- 210000004027 cell Anatomy 0.000 claims 27
- 239000002243 precursor Substances 0.000 claims 14
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100021592 Interleukin-7 Human genes 0.000 claims 3
- 102100020880 Kit ligand Human genes 0.000 claims 3
- 101710177504 Kit ligand Proteins 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 102000013135 CD52 Antigen Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- 210000003954 umbilical cord Anatomy 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000006402 Ductal Carcinoma Diseases 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102100027188 Thyroid peroxidase Human genes 0.000 claims 1
- 101710113649 Thyroid peroxidase Proteins 0.000 claims 1
- 201000011186 acute T cell leukemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 208000020615 rectal carcinoma Diseases 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2317—Interleukin-17 (IL-17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682706P | 2012-08-13 | 2012-08-13 | |
| US61/682,706 | 2012-08-13 | ||
| US201361799211P | 2013-03-15 | 2013-03-15 | |
| US61/799,211 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108761A Division RU2015108761A (ru) | 2012-08-13 | 2013-08-13 | Природные клетки-киллеры и их применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019124982A true RU2019124982A (ru) | 2019-09-02 |
Family
ID=50101590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019124982A RU2019124982A (ru) | 2012-08-13 | 2013-08-13 | Природные клетки-киллеры и их применение |
| RU2015108761A RU2015108761A (ru) | 2012-08-13 | 2013-08-13 | Природные клетки-киллеры и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015108761A RU2015108761A (ru) | 2012-08-13 | 2013-08-13 | Природные клетки-киллеры и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150225697A1 (https=) |
| EP (2) | EP3722416A1 (https=) |
| JP (4) | JP2015526088A (https=) |
| KR (3) | KR20220166873A (https=) |
| CN (2) | CN114134113A (https=) |
| AU (3) | AU2013302853A1 (https=) |
| BR (1) | BR112015003149A2 (https=) |
| CA (1) | CA2881792C (https=) |
| HK (1) | HK1211620A1 (https=) |
| MX (1) | MX2015001871A (https=) |
| RU (2) | RU2019124982A (https=) |
| WO (1) | WO2014028453A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| JP6493692B2 (ja) | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたｔリンパ球 |
| CN105916521A (zh) * | 2013-11-15 | 2016-08-31 | 人类起源公司 | 包含人胎盘灌注液细胞、其亚群的组合物及其用途 |
| BR112017014269A2 (pt) * | 2014-12-31 | 2018-03-27 | Anthrogenesis Corp | células exterminadoras naturais e usos das mesmas |
| JP6797803B2 (ja) * | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| EP3280796B1 (en) * | 2015-04-09 | 2019-09-11 | Universita' degli Studi di Genova | Population of human lymphoid precursors, method for their identification and uses thereof |
| JP6073417B2 (ja) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 |
| WO2017042393A1 (en) * | 2015-09-11 | 2017-03-16 | Emercell Sas | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease |
| EP3747472B1 (en) | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
| EA201890960A1 (ru) * | 2015-10-15 | 2018-10-31 | Селулэрити, Инк. | Натуральные киллеры и клетки ilc3 и их применение |
| CA3003923A1 (en) * | 2015-11-05 | 2017-05-11 | Glycostem Therapeutics B.V. | Composition for use in immunotherapy |
| CN106701677A (zh) * | 2015-11-18 | 2017-05-24 | 深圳爱生再生医学科技有限公司 | Nk细胞的体外扩增培养方法 |
| US20190037831A1 (en) * | 2016-02-01 | 2019-02-07 | Green Cross Lab Cell Corporation | Medium composition for cryopreservation of cell and use thereof |
| BR112018072701A2 (pt) * | 2016-05-07 | 2019-02-19 | Celularity, Inc. | métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| KR101866827B1 (ko) * | 2016-09-28 | 2018-07-19 | 한국원자력의학원 | 방사선 조사된 말초혈액단핵구를 이용한 고효율 자연살상세포의 제조방법 및 이를 이용한 항암 면역 세포치료제 조성물 |
| KR101846464B1 (ko) | 2016-11-14 | 2018-04-09 | 주식회사 파이안바이오테크놀로지 | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 |
| EP3556849A4 (en) * | 2016-12-14 | 2020-08-19 | Otsuka Pharmaceutical Factory, Inc. | MAMMAL CELL CRYOPRESERVATION LIQUID |
| JP2020503043A (ja) * | 2016-12-30 | 2020-01-30 | セルラリティ インコーポレイテッド | 遺伝子改変されたナチュラルキラー細胞 |
| IL309689B1 (en) * | 2017-02-28 | 2026-02-01 | Univ Central Florida Res Found Inc | PM21 particles to enhance NK cell migration to the bone marrow |
| US12129487B2 (en) * | 2017-03-27 | 2024-10-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to obtain lymphoid progenitors |
| CN107384859A (zh) * | 2017-09-05 | 2017-11-24 | 四川新生命干细胞科技股份有限公司 | 一种高纯度nk细胞的分离培养方法 |
| WO2019067792A1 (en) * | 2017-09-28 | 2019-04-04 | Celularity, Inc. | TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY |
| US11834677B2 (en) | 2017-10-02 | 2023-12-05 | Gamida Cell Ltd. | Expansion and use of expanded NK cell fractions |
| CN107904175B (zh) * | 2017-12-29 | 2018-09-25 | 广州沙艾生物科技有限公司 | 用于免疫细胞的诱导扩增的培养箱 |
| KR20210016567A (ko) * | 2018-05-30 | 2021-02-16 | 글리코스템 떼라퓨틱스 비.브이. | Car nk 세포 |
| EP3820994A1 (en) | 2018-07-10 | 2021-05-19 | Nantkwest, Inc. | Generating cik nkt cells from cord blood |
| CN109337870B (zh) * | 2018-12-24 | 2020-07-03 | 广东暨德康民生物科技有限责任公司 | 人Vγ9Vδ2T细胞扩增方法与培养基 |
| KR102032384B1 (ko) * | 2019-03-05 | 2019-11-08 | 주식회사 온코인사이트 | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 |
| KR102216710B1 (ko) * | 2019-03-27 | 2021-02-17 | 신지섭 | Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물 |
| EP3922715A4 (en) | 2019-04-17 | 2022-03-30 | CHA Biotech Co., Ltd. | NATURAL KILLER CELLS WITH INCREASED ANTI-CANCER EFFECTS AND IMMUNOTHERAPEUTIC USE THEREOF |
| KR102233660B1 (ko) * | 2019-05-15 | 2021-03-30 | (주)포에버엔케이 | 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트 |
| IT201900023922A1 (it) * | 2019-12-13 | 2021-06-13 | Univ Degli Studi Genova | Popolazione cellulare progenitrice CD56-CD16+PerfnegCD7- e progenie cellulare NK CD94/NKG2C+KIR+CD57+ originata da detta popolazione cellulare CD56-CD16+PerfnegCD7-, loro ottenimento e loro usi |
| EP4114415A1 (en) | 2020-03-06 | 2023-01-11 | Sorrento Therapeutics, Inc. | Innate immunity killer cells targeting psma positive tumor cells |
| CN112029722A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种nk细胞培养基及其应用 |
| CN112029721A (zh) * | 2020-09-09 | 2020-12-04 | 广东昭泰体内生物医药科技有限公司 | 一种活性增强型nk细胞的制备方法 |
| CN112266900A (zh) * | 2020-10-30 | 2021-01-26 | 广东康盾生物工程技术有限公司 | 一种car-nk细胞的培养方法 |
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN113416701B (zh) * | 2021-07-28 | 2023-05-09 | 新疆西部赛澳生物科技有限责任公司 | 一种nk细胞培养基及培养方法 |
| WO2023011114A1 (zh) * | 2021-08-06 | 2023-02-09 | 中国科学院动物研究所 | 一种ric细胞及其制备方法和应用 |
| JPWO2023038037A1 (https=) * | 2021-09-08 | 2023-03-16 | ||
| CN113801846B (zh) * | 2021-09-22 | 2024-06-04 | 南京艾尔普再生医学科技有限公司 | 一种从人诱导多能干细胞分化为自然杀伤细胞的方法 |
| CN114891856B (zh) * | 2022-05-16 | 2025-08-15 | 武汉科技大学 | 大队列样本单细胞富集和混样建库测序方法 |
| CN114736859B (zh) * | 2022-06-13 | 2022-08-19 | 广东先康达生物科技有限公司 | 一种脐带血nk细胞的培养液及培养方法 |
| WO2024101863A1 (ko) * | 2022-11-07 | 2024-05-16 | 마루테라퓨틱스 주식회사 | 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법 |
| US20240279607A1 (en) * | 2023-02-17 | 2024-08-22 | FullHope Biomedical Co., Ltd. | Pharmaceutical composition comprising modified natural killer cells and antigen-specific t cells, manufacturing method thereof, and method of using the same |
| CN117603809A (zh) * | 2023-12-06 | 2024-02-27 | 威海紫光科技园有限公司 | 一种应用于nk细胞制备过程中复苏的温度控制方法及系统 |
| CN117946971B (zh) * | 2023-12-14 | 2025-07-15 | 深圳泽医细胞治疗集团有限公司 | 一种用于诱导C1型iNKT细胞的培养基、培养方法及其应用 |
| WO2025160465A1 (en) | 2024-01-26 | 2025-07-31 | Celularity Inc. | A method of treating signs or symptoms of the aging process |
| CN118370308B (zh) * | 2024-04-18 | 2025-11-11 | 维赛(佛山)生物科技有限公司 | 一种临床用犬自然杀伤细胞冷藏保存液及其制备方法和应用 |
| WO2025225667A1 (ja) * | 2024-04-26 | 2025-10-30 | 日機装株式会社 | 凍結された腎細胞凝集体を含むプレート、それを用いた薬物動態検査用キット、毒性検査用キット及び創薬開発用キット |
| CN120005821B (zh) * | 2025-04-21 | 2025-07-25 | 上海华颜医药科技有限公司 | 一种免疫细胞的培养方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5190556A (en) | 1991-03-19 | 1993-03-02 | O.B. Tech, Inc. | Cord cutter sampler |
| US5552267A (en) | 1992-04-03 | 1996-09-03 | The Trustees Of Columbia University In The City Of New York | Solution for prolonged organ preservation |
| US5372581A (en) | 1993-07-21 | 1994-12-13 | Minneapolis Children's Services Corporation | Method and apparatus for placental blood collection |
| DK1349918T3 (da) | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
| EP2316919B1 (en) | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| AU2002363322A1 (en) * | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| PT2471904T (pt) | 2005-12-29 | 2019-02-25 | Celularity Inc | População de células estaminais placentárias |
| CA2633980A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| US9193953B2 (en) * | 2007-03-27 | 2015-11-24 | Ipd-Therapeutics B.V. | Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells |
| ES2666746T3 (es) * | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Métodos para generar linfocitos citolíticos naturales |
| US9476029B2 (en) * | 2010-11-13 | 2016-10-25 | Lung-Ji Chang | Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells |
| WO2012128622A1 (en) * | 2011-03-18 | 2012-09-27 | Ipd-Therapeutics B.V. | Generation of nk cells and nk-cell progenitors |
-
2013
- 2013-08-13 JP JP2015527530A patent/JP2015526088A/ja active Pending
- 2013-08-13 MX MX2015001871A patent/MX2015001871A/es unknown
- 2013-08-13 KR KR1020227042037A patent/KR20220166873A/ko not_active Ceased
- 2013-08-13 HK HK15112433.3A patent/HK1211620A1/xx unknown
- 2013-08-13 CN CN202111362929.5A patent/CN114134113A/zh active Pending
- 2013-08-13 RU RU2019124982A patent/RU2019124982A/ru unknown
- 2013-08-13 AU AU2013302853A patent/AU2013302853A1/en not_active Abandoned
- 2013-08-13 CA CA2881792A patent/CA2881792C/en active Active
- 2013-08-13 KR KR1020217017107A patent/KR20210076150A/ko not_active Ceased
- 2013-08-13 US US14/421,059 patent/US20150225697A1/en not_active Abandoned
- 2013-08-13 EP EP20162827.8A patent/EP3722416A1/en not_active Withdrawn
- 2013-08-13 BR BR112015003149A patent/BR112015003149A2/pt not_active Application Discontinuation
- 2013-08-13 RU RU2015108761A patent/RU2015108761A/ru not_active Application Discontinuation
- 2013-08-13 CN CN201380053349.5A patent/CN105008516A/zh active Pending
- 2013-08-13 KR KR1020157006395A patent/KR20150063374A/ko not_active Ceased
- 2013-08-13 EP EP13829894.8A patent/EP2882847A4/en not_active Withdrawn
- 2013-08-13 WO PCT/US2013/054677 patent/WO2014028453A2/en not_active Ceased
-
2018
- 2018-07-12 JP JP2018132290A patent/JP2018183161A/ja active Pending
-
2019
- 2019-06-07 AU AU2019204020A patent/AU2019204020A1/en not_active Abandoned
-
2020
- 2020-07-16 JP JP2020121929A patent/JP2020188782A/ja not_active Withdrawn
-
2022
- 2022-02-14 AU AU2022200976A patent/AU2022200976A1/en not_active Abandoned
- 2022-12-07 JP JP2022195426A patent/JP2023036639A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150225697A1 (en) | 2015-08-13 |
| MX2015001871A (es) | 2015-09-21 |
| AU2013302853A1 (en) | 2015-03-05 |
| CA2881792A1 (en) | 2014-02-20 |
| HK1211620A1 (en) | 2016-05-27 |
| AU2019204020A1 (en) | 2019-06-27 |
| AU2022200976A1 (en) | 2022-03-03 |
| EP3722416A1 (en) | 2020-10-14 |
| JP2018183161A (ja) | 2018-11-22 |
| JP2015526088A (ja) | 2015-09-10 |
| CA2881792C (en) | 2024-02-27 |
| WO2014028453A3 (en) | 2014-10-09 |
| JP2020188782A (ja) | 2020-11-26 |
| CN114134113A (zh) | 2022-03-04 |
| KR20220166873A (ko) | 2022-12-19 |
| JP2023036639A (ja) | 2023-03-14 |
| EP2882847A4 (en) | 2016-03-23 |
| WO2014028453A2 (en) | 2014-02-20 |
| BR112015003149A2 (pt) | 2017-08-08 |
| CN105008516A (zh) | 2015-10-28 |
| EP2882847A2 (en) | 2015-06-17 |
| KR20150063374A (ko) | 2015-06-09 |
| KR20210076150A (ko) | 2021-06-23 |
| RU2015108761A (ru) | 2016-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019124982A (ru) | Природные клетки-киллеры и их применение | |
| JP2015526088A5 (https=) | ||
| JP2013532469A5 (https=) | ||
| Aponte et al. | Stemness in cancer: stem cells, cancer stem cells, and their microenvironment | |
| Bournazou et al. | Targeting the tumor microenvironment: JAK-STAT3 signaling | |
| Luo et al. | Shaping immune responses in the tumor microenvironment of ovarian cancer | |
| Ko et al. | Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice | |
| MX2024014142A (es) | Novedosos inhibidores de molecula peque?a de factores de transcripcion tead | |
| Shiozawa et al. | The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites | |
| Woiterski et al. | Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome | |
| JP2023171766A5 (https=) | ||
| Klopp et al. | Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? | |
| Farahzadi et al. | Targeting the stem cell niche micro-environment as therapeutic strategies in aging | |
| Ben-Baruch | The tumor-promoting flow of cells into, within and out of the tumor site: regulation by the inflammatory axis of TNFα and chemokines | |
| NZ747910A (en) | Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells | |
| NZ605505A (en) | Methods of generating natural killer cells | |
| NZ587440A (en) | Antibodies specific for human integrin alpha 5 - beta 1 and their uses for treating tumours | |
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| Martínez-Climent et al. | Somatic stem cells and the origin of cancer | |
| WO2016135559A3 (en) | Materials and methods for treatment of human genetic diseases including hemoglobinopathies | |
| JP2010540532A5 (https=) | ||
| JP2018502115A5 (https=) | ||
| RU2015134394A (ru) | Перепрограммирование эндотелия человека в гемопоэтических предшественников множественных линий дифференцировки с использованием определенных факторов | |
| WO2010051634A9 (en) | Human progenitor t-cells | |
| Guillaume et al. | The crosstalk between adipose-derived stem or stromal cells (ASC) and cancer cells and ASC-mediated effects on cancer formation and progression—ASCs: safety hazard or harmless source of tropism? |